{"id":"baricitinib-dexamethasone","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection (bacterial, viral, fungal)"},{"rate":null,"effect":"Hyperglycemia"},{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Thromboembolism"},{"rate":null,"effect":"Insomnia"},{"rate":null,"effect":"Mood changes"}]},"_chembl":{"chemblId":"CHEMBL2105759","moleculeType":"Small molecule","molecularWeight":"371.43"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Baricitinib is a JAK inhibitor that blocks Janus kinase signaling, reducing production of pro-inflammatory cytokines like IL-6 and TNF-α. Dexamethasone is a corticosteroid that suppresses immune cell activation and inflammatory mediator release. The combination targets multiple points in the inflammatory cascade, particularly relevant in severe inflammatory conditions such as COVID-19 or severe respiratory infections.","oneSentence":"Baricitinib inhibits JAK1/JAK2 kinases to suppress inflammatory cytokine signaling, while dexamethasone provides additional glucocorticoid-mediated immunosuppression.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:37.632Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"COVID-19 (severe respiratory disease)"},{"name":"Severe inflammatory respiratory conditions"}]},"trialDetails":[{"nctId":"NCT06768840","phase":"PHASE2, PHASE3","title":"Vitiligo, New Treatment and Serum s100B","status":"RECRUITING","sponsor":"South Valley University","startDate":"2024-10-02","conditions":"Vitiligo, Generalized","enrollment":50},{"nctId":"NCT02735707","phase":"PHASE3","title":"Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia","status":"RECRUITING","sponsor":"UMC Utrecht","startDate":"2016-04-11","conditions":"Community-acquired Pneumonia, Influenza, COVID-19","enrollment":20000},{"nctId":"NCT04970719","phase":"PHASE3","title":"Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus","status":"WITHDRAWN","sponsor":"Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders","startDate":"2021-07-10","conditions":"COVID-19 Pneumonia","enrollment":""},{"nctId":"NCT04890626","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Different Treatments in Patients With COVID-19","status":"COMPLETED","sponsor":"Instituto de Investigación Hospital Universitario La Paz","startDate":"2020-04-04","conditions":"SARS-CoV-2 Infection","enrollment":356},{"nctId":"NCT04381936","phase":"PHASE3","title":"Randomised Evaluation of COVID-19 Therapy","status":"RECRUITING","sponsor":"University of Oxford","startDate":"2020-03-19","conditions":"Severe Acute Respiratory Syndrome","enrollment":70000},{"nctId":"NCT05932524","phase":"PHASE2","title":"Low-dose Baricitinib Plus High-dose Dexamethasone for Patients With Newly Diagnosed Immune Thrombocytopenia","status":"UNKNOWN","sponsor":"Peking University People's Hospital","startDate":"2023-07-07","conditions":"Immune Thrombocytopenia","enrollment":132},{"nctId":"NCT05187793","phase":"PHASE3","title":"Study of Efficacy of Different Treatment Regimens of Olokizumab","status":"UNKNOWN","sponsor":"R-Pharm","startDate":"2021-07-08","conditions":"COVID-19","enrollment":198},{"nctId":"NCT04640168","phase":"PHASE3","title":"Adaptive COVID-19 Treatment Trial 4 (ACTT-4)","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2020-12-02","conditions":"COVID-19","enrollment":1010},{"nctId":"NCT05279391","phase":"NA","title":"Combination of Inhaled DNase, Baricitinib and Tocilizumab in Severe COVID-19","status":"UNKNOWN","sponsor":"Democritus University of Thrace","startDate":"2020-10-25","conditions":"COVID-19 Severe Respiratory Failure","enrollment":150},{"nctId":"NCT04832880","phase":"PHASE3","title":"Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)","status":"UNKNOWN","sponsor":"ASST Fatebenefratelli Sacco","startDate":"2021-04-06","conditions":"Covid19","enrollment":4000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":129,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Baricitinib + dexamethasone","genericName":"Baricitinib + dexamethasone","companyName":"Instituto de Investigación Hospital Universitario La Paz","companyId":"instituto-de-investigaci-n-hospital-universitario-la-paz","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Baricitinib in combination with dexamethasone is being studied as a potential treatment for various conditions, including SARS-CoV-2 Infection, COVID-19, and COVID-19 Severe Respiratory Failure. The exact mechanism of action of baricitinib + dexamethasone is not specified in the provided facts, but baricitinib is known to be a Janus kinase (JAK) inhibitor, according to ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}